Ligand Pharmaceuticals (LGND) Stock: Buy, Sell, or Hold?
LGND - Ligand Pharmaceuticals Inc.
$284.47
-4.78 (-1.65%)
▼
5d:
-1.82%
30d:
-3.0%
90d:
+11.75%
BUY
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When LGND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LGND shows positive signals but monitor for confirmation. Market pricing in 1.5% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: LGND shows positive signals but monitor for confirmation. Market pricing in 1.5% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$529.91
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$329.03
13.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LGND is currently trading at $284.47, which is considered slightly low relative to its 30-day fair value range of $283.50 to $294.04. The stock's valuation (Forward PE: 23.8) is in line with its historical norms (22.8). At these levels, the market is pricing in 1.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LGND is in a strong uptrend. Immediate support is located at $275.60, while resistance sits at $294.00.
Market Sentiment: LGND scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $342.82 (+20.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LGND is in a strong uptrend. Immediate support is located at $275.60, while resistance sits at $294.00.
Market Sentiment: LGND scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $342.82 (+20.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$283.50 -
$294.04
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
93.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.5% below Wall St target ($342.82)
- NEUTRAL: Market pricing in 1.5% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 69/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$283.50 -
$294.04
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$16.81
(5.9%)
Support & Resistance Levels
Support Level
$275.60
Resistance Level
$294.00
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.84
Wall Street Target
$342.82
(+20.5%)
Revenue Growth (YoY)
33.7%
Earnings Growth (YoY)
825.0%
Profit Margin
67.9%
Valuation Premium vs History
+1.5% premium
PE vs Historical
23.8 vs 22.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$288.74
(+2%)
2-Year Target
$293.07
(+3%)
3-Year Target
$297.46
(+5%)
3-Yr Target (if PE normalizes)
(PE: 24→23)
PE COMPRESSION
$284.55
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.8, Growth: 28.1%)
$598.32
(+110%)
Base:
(SPY PE: 20.2, Growth: 28.1%)
$506.31
(+78%)
Bear:
(PE: 17.1, Growth: 28.1%)
$430.37
(+51%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 29.70 | Current EPS (TTM): $9.74
Bull Case
$389.88
(+37%)
Analyst growth 22.5%, PE expands to 32.7
Base Case
$354.43
(+25%)
Market implied 22.5%, PE stable at 29.7
Bear Case
$196.69
(-31%)
Severe decline -20.0%, PE contracts to 25.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 13, 2026 1:27 PM ET
Data refreshes hourly during market hours. Next update: 2:27 PM
Data refreshes hourly during market hours. Next update: 2:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LGND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
John W Kozarich
SELL
467 shares
2026-04-01
Andrew Reardon
SELL
5000 shares
2026-04-01
Stephen L Sabba
SELL
1000 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
Advanced LGND Option Strategies
Professional options setups generated by AI based on today's LGND price and gamma walls.
